Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Peer Reviewed
See detailIatrogenic thyrotoxicosis. Causal circumstances, pathophysiology and principles of treatment. Review of the literature
Meurisse, Michel ULg; Preud'Homme, Laurence ULg; Lamberty, Geoffrey ULg et al

in Acta Chirurgica Belgica (2001), 101(6), 257-266

Thyrotoxicosis is the clinical syndrome that results when tissues are exposed to high levels of circulating thyroid hormones. In most instances, thyrotoxicosis is due to hyperthyroidism, a term reserved ... [more ▼]

Thyrotoxicosis is the clinical syndrome that results when tissues are exposed to high levels of circulating thyroid hormones. In most instances, thyrotoxicosis is due to hyperthyroidism, a term reserved for disorders characterized by overproduction of thyroid hormones by the thyroid gland. Nevertheless, thyrotoxicosis may also result from a variety of conditions other than thyroid hyperfunction. The present report focuses on the etiologies, pathophysiology and treatment of iatrogenic thyrotoxicosis. Iatrogenic thyrotoxicosis may be caused by 1) subacute thyroiditis (a result of lymphocytic infiltration, cellular injury, trauma or radiation) with release of preformed hormones into circulation, 2) excessive ingestion of thyroid hormones ("thyrotoxicosis factitia"), 3) iodine-induced hyperthyroidism (radiological contrast agents, topical antiseptics or other medications). Among these causes of iatrogenic thyrotoxicosis, that induced by the iodine overload and cytotoxicity associated with amiodarone represents a significant challenge. Successful management of amiodarone-induced thyrotoxicosis requires close cooperation between endocrinologists and endocrine Surgeons. Surgical treatment may have a leading yet often underestimated role in view of the potential life-threatening severity of this disease, whereas others kinds of iatrogenic thyrotoxicosis are usually treated conservatively. [less ▲]

Detailed reference viewed: 15 (1 ULg)
Full Text
See detailL'iatrogénie cytostatique simulatrice. Apparence d'un pityriasis lichénoïde aigu induit par le pemetrexed.
SABATIELLO, Murielle ULg; Willemaers, Valentine; Lesuisse, Marianne et al

in Dermatologie Actualité (2011), 125

Detailed reference viewed: 43 (1 ULg)
Full Text
Peer Reviewed
See detailL'iatrogenie psoriasique.
Franchimont, Claudine ULg; PIERARD, Gérald ULg

in Revue Médicale de Liège (2012), 67(3), 139-42

Psoriasis is a common genetic disorder that may be initiated (drug-induced psoriasis) or exacerbated (drug-triggered psoriasis) by some drug intakes. Beta-blockers, lithium, some antimelarial drugs, non ... [more ▼]

Psoriasis is a common genetic disorder that may be initiated (drug-induced psoriasis) or exacerbated (drug-triggered psoriasis) by some drug intakes. Beta-blockers, lithium, some antimelarial drugs, non steroidal anti-inflammatory agents and tetracyclines are recognized to influence the clinical course of psoriasis. Other drugs are likely or possibly involved in this process. [less ▲]

Detailed reference viewed: 25 (0 ULg)
Full Text
Peer Reviewed
See detailThe IBA Guidelines on Party Representation in International Arbitration
Caprasse, Olivier ULg

in Revue de la Faculté de Droit de l'Université de Liège (2013), (305-318),

Detailed reference viewed: 45 (4 ULg)
Full Text
Peer Reviewed
See detailL'ibandronate (Bonviva), dans le traitement de l'osteoporose postmenopausique
Reginster, Jean-Yves ULg

in Revue Médicale de Liège (2006), 61(11), 783-6

Ibandronate is a nitrogen-containing bisphosphonate which has been shown to reduce vertebral fracture rates, when given orally either daily or intermittently. Non-vertebral antifracture efficacy of ... [more ▼]

Ibandronate is a nitrogen-containing bisphosphonate which has been shown to reduce vertebral fracture rates, when given orally either daily or intermittently. Non-vertebral antifracture efficacy of ibandronate has been derived from a post-hoc analysis focusing on patients at high risk of developing non-vertebral fractures (low bone mineral density at the femoral neck). Once-monthly administration of oral ibandronate has been linked to significantly greater increases in bone mineral density, at the spine, hip and femoral neck, compared to daily formulation. This monthly formulation has a safety profile similar to the one observed with the daily administration of the compound. Adherence to monthly bisphosphonates appears to be significantly higher than for daily or weekly administration. [less ▲]

Detailed reference viewed: 91 (4 ULg)
Full Text
Peer Reviewed
See detailIbandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data.
Cranney, Ann; Wells, G. A.; Yetisir, E. et al

in Osteoporosis International (2009), 20(2), 291-7

SUMMARY: This analysis was conducted to assess the effect of high versus lower doses of ibandronate on nonvertebral fractures. The results were adjusted for clinical fracture, age, and bone density. The ... [more ▼]

SUMMARY: This analysis was conducted to assess the effect of high versus lower doses of ibandronate on nonvertebral fractures. The results were adjusted for clinical fracture, age, and bone density. The treatment effect was dose-dependent. Higher doses of ibandronate significantly reduced the risk of nonvertebral fractures more effectively compared with lower doses. INTRODUCTION: The objective of this study was to assess the efficacy of different doses of ibandronate on nonvertebral fractures in a pooled analysis. METHODS: Eight randomized trials of ibandronate were reviewed for inclusion. Alternative definitions of high versus low doses based on annual cumulative exposure (ACE) were explored. A time-to-event analysis was conducted using Kaplan-Meier methodology. Hazard ratios (HR) were derived using Cox regression and adjusted for covariates. RESULTS: Combining higher ACE doses of > or = 10.8 mg (150 mg once monthly, 3 mg i.v. quarterly, and 2 mg i.v. every 2 months) versus ACE doses of 5.5 mg, from two trials, resulted in an HR 0.62 (95% CI 0.396-0.974, p = 0.038). There was a dose-response trend with increasing ACE doses (7.2-12 mg) versus ACE of 5.5 mg. CONCLUSIONS: A dose-response effect on nonvertebral fractures was observed when comparing high with low ACE doses. A significant reduction in nonvertebral fractures was noted when pooling data from trials using ACE doses of > or = 10.8 mg versus ACE < or = 7.2 mg; and with ACE > or = 10.8 mg versus ACE of 5.5 mg (38% reduction). Higher ibandronate dose levels (150 mg monthly or 3 mg i.v. quarterly) significantly reduced nonvertebral fracture risk in postmenopausal women. [less ▲]

Detailed reference viewed: 70 (4 ULg)
Full Text
Peer Reviewed
See detailIbandronate in profile: drug characteristics and clinical efficacy.
Reginster, Jean-Yves ULg; Neuprez, Audrey; Bruyère, Olivier ULg

in Expert Opinion on Drug Metabolism & Toxicology (2008), 4(7), 941-51

BACKGROUND: Postmenopausal osteoporosis is a serious, chronic condition, for which nitrogen-containing bisphosphonates are now one of the treatments of choice. OBJECTIVE: To review the profile of ... [more ▼]

BACKGROUND: Postmenopausal osteoporosis is a serious, chronic condition, for which nitrogen-containing bisphosphonates are now one of the treatments of choice. OBJECTIVE: To review the profile of ibandronate, a monthly oral (150 mg) or quarterly intravenous injection (3 mg) of bisphosphonate. METHODS: The literature search was limited to publications of ibandronate data. RESULTS/CONCLUSION: Ibandronate is rapidly absorbed and distributed in the bone; it is not metabolised and is excreted in urine. Clinical trial data have demonstrated the efficacy of ibandronate in reducing fracture risk, increasing bone mineral density and reducing bone turnover. These data are supported by recent meta-analyses and a large database study that have demonstrated antifracture efficacy with the ibandronate regimens used in clinical practice. Overall, ibandronate has generally been well tolerated. Therefore, ibandronate is a useful treatment for postmenopausal osteoporosis. [less ▲]

Detailed reference viewed: 38 (4 ULg)
Full Text
Peer Reviewed
See detailIbandronate in the management of postmenopausal osteoporosis
Reginster, Jean-Yves ULg; Hiligsmann, Mickaël ULg; Rabenda, Véronique ULg et al

in Clinical Medicine. Therapeutics (2009), 1

Detailed reference viewed: 43 (11 ULg)
Full Text
Peer Reviewed
See detailIbandronate: a new perspective in the treatment of osteoporosis
Reginster, Jean-Yves ULg; Burlet, N.; LECART, Marie-Paule ULg

in Therapy (2005), 2

Detailed reference viewed: 14 (2 ULg)
Full Text
Peer Reviewed
See detailIBD mapping of recessive traits in livestock: application to map the bovine syndactyly locus to chromosome 15
Charlier, Carole ULg; Farnir, Frédéric ULg; Berzi, P. et al

in Genome Research (1996), 6

Twelve animals affected with syndactyly or mulefoot were sampled in the Dutch black-and-white cattle population. Analysis of the pedigree data reveal that all of these individuals traced back to a single ... [more ▼]

Twelve animals affected with syndactyly or mulefoot were sampled in the Dutch black-and-white cattle population. Analysis of the pedigree data reveal that all of these individuals traced back to a single acknowledged carrier founder individual. Between seven and nine generations separated the founder from its 12 affected descendents. The 12 affected offspring were genotyped for a battery of 213 microsatellites spanning the 29 bovine autosomes. The resulting genotypes were analyzed using a maximum likelihood approach searching for shared homozygous haplotypes among affected individuals. Three candidate regions for the syndactyly locus emerged from this initial screening. syndactyly was shown to map to one of these candidate regions on chromosome 15 by genotyping 29 additional individuals linking founder and affected offspring and performing a conventional linkage analysis with the LINKAGE programs. This study illustrates the potential of identity-by-descent mapping in livestock populations. [less ▲]

Detailed reference viewed: 27 (3 ULg)
Full Text
See detailIberian Margin: The Rias
Álvarez–Salgado, X. A.; Borges, Alberto ULg; Figueiras, F. G. et al

in Carbon and Nutrient Fluxes in Continental Margins (2009)

Detailed reference viewed: 40 (1 ULg)
Full Text
See detailIBISCA-Panama, a large-scale study of arthropod beta-diversity and vertical stratification in a lowland rainforest: rationale, description of study sites and field methodology
Basset, Yves; Corbara, Bruno; Barrios, Hector et al

in Bulletin de l'Institut Royal des Sciences Naturelles de Belgique. Entomologie (2007), 77

Detailed reference viewed: 12 (4 ULg)
Peer Reviewed
See detailIbn ʿAbd al-Ẓāhir, Muḥyī l-Dīn
Bauden, Frédéric ULg

in Encyclopaedia of Islam Three (2015)

Detailed reference viewed: 15 (2 ULg)
Full Text
Peer Reviewed
See detailIBR and BVD control : the key to successful herd management
Makoschey, B.; Franken, P.; Mars, J. M. H. et al

in Berliner und Munchener Tierarztliche Wochenschrift (2010), 123

Detailed reference viewed: 40 (12 ULg)
See detailIC and Microsystem Micro-assembly and Packaging
Stoukatch, Serguei ULg; Saint-Mard, Michel

Scientific conference (2010, March 18)

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailICC Model Confidentiality Agreement
Caprasse, Olivier ULg

in Revue de la Faculté de Droit de l'Université de Liège (2008)

Detailed reference viewed: 130 (3 ULg)
See detailIce Covered Seas and Ice Edges: Physical, Chemical and Biological Processes and Interactions
Nihoul, Jacques ULg; Djenidi, Salim ULg

Book published by Elsevier Science (1992)

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailIce storage (ISS) : simulation of a typical HVAC primary plant equipped with an ice storage unit.
Adam, Ch.; Andre, Philippe ULg

(2003, August)

Within the framework of energy management in a tertiary building, it is necessary to evaluate the possibilities of cold energy storage. This study includes the consideration of ice storage for the ... [more ▼]

Within the framework of energy management in a tertiary building, it is necessary to evaluate the possibilities of cold energy storage. This study includes the consideration of ice storage for the airconditioning of the buildings. To compare objectively the operating strategies, the manager needs to reproduce the ISS performances for the same conditions (building, cooling and electrical demands, climate conditions,...). He needs also informations to chose the appropriate plant configuration or operating strategy to meet the global cooling demand taking into account the characteristics of the tank, of the demand curve,... at each moment. A simulation model of an entire HVAC primary plant should provide this information. This paper focuses on the adaptation of a latent storage model to an example of ISS. In order to validate the model the results of the simulation are compared to the performances of a small-size. [less ▲]

Detailed reference viewed: 42 (0 ULg)
Full Text
Peer Reviewed
See detailIce storage system (ISS) : phase change modelling (TRNSYS 15). Simulation of a typical HVAC primary plant equipped with an ice sotrage unit.
Adam, Ch.; Andre, Philippe ULg

in Proceedings of SSB'2002 congress (2002, December)

An ice storage can be an interesting option in a HVAC plant. It reduces the electricity costs and increases the HVAC plant capabilities. ISS reduces the on-peak power and shifts the cooling demand from ... [more ▼]

An ice storage can be an interesting option in a HVAC plant. It reduces the electricity costs and increases the HVAC plant capabilities. ISS reduces the on-peak power and shifts the cooling demand from the on-peak hours to the off-peak hours. ISS increases the available HVAC plant power, and then, the internal comfort. To store cold energy requires the selection of operating strategies. The objective of these strategies is to meet the global cooling demand of the building. Each strategy offers different technical and economical characteristics. The typical questions the manager of an HVAC plant has to solve are: Which is optimal ice storage tank in my case? Which cooling power? Which cooling capacity? How to run the HVAC plant to minimize the cost? To compare objectively the strategies, the manager needs to reproduce the ISS performances for the same conditions (building, cooling and electrical demands, climate conditions,...). He needs also informations to chose the appropriate plant configuration or operating strategy to meet the global cooling demand taking into account the characteristics of the tank, of the demand curve,... at each moment. A simulation model of an entire HVAC primary plant should provide this information. [less ▲]

Detailed reference viewed: 145 (0 ULg)